Neuprozyme Therapeutics ApS — Credit Rating and Financial Key Figures

Neuprozyme Therapeutics ApS (CVR number: 40010106) is a company from RUDERSDAL. The company recorded a gross profit of -27.5 kDKK in 2024. The operating profit was -27.5 kDKK, while net earnings were -25.6 kDKK. The profitability of the company measured by Return on Assets (ROA) was -21.6 %, which can be considered poor and Return on Equity (ROE) was -26.9 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at 75.5 %, a level that can be considered to be good. This shows that a large part of the company's assets are funded by shareholders' equity, reducing financial risk. Neuprozyme Therapeutics ApS's liquidity measured by quick ratio was 4.1 which is at a very high level. Thus, the company demonstrates exceptional financial stability, possessing a significant surplus of liquid assets over its short-term liabilities.